# A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2

Study · id `cardio:ct-nct06952530` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06952530](<https://clinicaltrials.gov/study/NCT06952530>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06952530

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 487 participants.

## Technical summary

Registry record NCT06952530. Randomized; double masking; primary purpose treatment. Start 2025-04-30 (actual); primary completion 2027-09 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 487 participants (planned count; ClinicalTrials.gov record NCT06952530, source copy `cardio:ctgov-nct06952530-2026-05-29`, retrieved 2026-10-26)
- Started: 2025-04-30 (actual) (ClinicalTrials.gov record NCT06952530, source copy `cardio:ctgov-nct06952530-2026-05-29`, retrieved 2026-10-26)
- Primary completion: 2027-09 (anticipated) (ClinicalTrials.gov record NCT06952530, source copy `cardio:ctgov-nct06952530-2026-05-29`, retrieved 2026-10-26)
- Completion: 2027-09 (anticipated) (ClinicalTrials.gov record NCT06952530, source copy `cardio:ctgov-nct06952530-2026-05-29`, retrieved 2026-10-26)
- Countries: United States; Argentina; China; Czechia; Germany; Greece; India; Japan; Poland; Puerto Rico; Spain (ClinicalTrials.gov record NCT06952530, source copy `cardio:ctgov-nct06952530-2026-05-29`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06952530-2026-05-29`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
- Condition: Hypertension
- Intervention (Drug): Orforglipron
- Intervention (Drug): Placebo
- Lead sponsor: Eli Lilly and Company
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Eli Lilly and Company (`cardio:eli-lilly`)

## Provenance

Content hash: a0fecfcbc50ec04d0589be4bb96ad88728e0f56f04d6308f242411ff150fd83c
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
